Panuveitis Global Market Report 2025

The panuveitis market size has grown rapidly in recent years. It will grow from $4.05 billion in 2024 to $4.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the prevalence of autoimmune and infectious diseases, the increasing use of corticosteroids, the rising adoption of biologics, the growing demand for ophthalmic imaging, and expanding research investment in infectious causes.

The panuveitis market size is expected to see rapid growth in the next few years. It will grow to $6.58 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the expanding use of biologic therapies, increasing demand for personalized medicine, the rising prevalence of uveitis-linked diseases, higher investments in ophthalmic research, and growing disease awareness. Major trends expected during this period include the increasing adoption of biologic therapies, the development of sustained-release drug delivery systems, the expansion of personalized medicine approaches, advancements in AI-driven diagnosis and treatment, and the rise of minimally invasive surgical techniques.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the panuveitis market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues. This rising prevalence is attributed to factors such as genetic predisposition, environmental influences such as pollution and dietary changes, and greater exposure to infections and stressors that can trigger immune system dysregulation. Autoimmune disorders are advancing panuveitis treatment by promoting research into immune system modulation, as many cases of panuveitis are linked to autoimmune activity. For instance, in May 2023, the University of Oxford, a UK-based research institution, reported that autoimmune disorders affect 10% of the global population, with 13% of women and 7% of men impacted. As a result, the increasing occurrence of autoimmune disorders is fueling the expansion of the panuveitis market.

Leading companies in the panuveitis market are prioritizing the development of advanced slow-release intravitreal injection formulations to enhance patient compliance and treatment effectiveness. A slow-release intravitreal injection formulation is a drug delivery system that gradually administers medication into the eye's vitreous humor over an extended period, ensuring sustained therapeutic effects while minimizing the need for frequent dosing. For example, in August 2022, Tarsier Pharma, an Israel-based clinical-stage company, announced the development of TRS02, a potential immunomodulator for the treatment of retinal diseases. This innovative therapy is designed to address various back-of-the-eye conditions with inflammatory pathologies, including posterior uveitis (panuveitis) and diabetic macular edema. TRS02, developed using Tarsier's proprietary technology platform, is advancing toward investigational new drug (IND) submission following successful preclinical milestones.

In July 2023, Harrow Health Inc., a US-based pharmaceutical company, acquired Santen Pharmaceutical Co., Ltd. for an undisclosed sum. This acquisition enables Harrow to expand its portfolio by integrating Santen's expertise in developing innovative treatments for uveitis and panuveitis. Santen Pharmaceutical Co. Ltd., a Japan-based company, specializes in treatments for panuveitis.

Major players in the panuveitis market are Pfizer Inc., AbbVie, Boehringer Ingelheim International GmbH, Amgen, Teva Pharmaceuticals, Sandoz, Organon group of companies, Zydus Lifesciences Ltd., Mallinckrodt plc, Alvotech, EyePoint Pharmaceuticals Inc., Affibody Medical AB, Alumis Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Revolo Biotherapeutics Ltd., Tarsier Pharma, Priovant Therapeutics Inc., Mylan N.V., Clearside Biomedical Inc., pSivida Corp.

North America was the largest region in the panuveitis market in 2024. The regions covered in panuveitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the panuveitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Panuveitis is an inflammatory condition that affects all three layers of the uvea include the iris, ciliary body, and choroid within the eye. If left untreated, it can cause pain, blurred vision, and potentially lead to vision loss. The primary goal of treatment is to control inflammation, alleviate symptoms, and prevent further eye damage that could impair vision. Timely intervention is crucial for maintaining eye health and preserving sight.

The main types of panuveitis include infectious and non-infectious panuveitis. Infectious panuveitis is caused by infectious agents and requires prompt diagnosis and treatment to prevent severe eye complications and vision impairment. Treatment options include pharmacological therapy, surgical interventions, and phototherapy, administered via oral, intravitreal, and topical routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, ensuring accessibility for patients.

The panuveitis market research report is one of a series of new reports that provides panuveitis market statistics, including the panuveitis industry global market size, regional shares, competitors with the panuveitis market share, detailed panuveitis market segments, market trends, and opportunities, and any further data you may need to thrive in the panuveitis industry. This panuveitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The panuveitis market consists of revenues earned by entities providing services such as pharmaceutical treatment, surgical interventions, diagnostic services, and supportive care. The market value includes the value of related goods sold by the service providers or included within the service offering. The panuveitis market also includes sales of diagnostic tools, pharmaceuticals, biologic agents, immunosuppressive drugs, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.